|
1
|
Chen B, Jin S, Bai B, Li Z, Ni C and Liu
Y: Knockdown of interferon-stimulated gene 15 affects the
sensitivity of hepatocellular carcinoma cells to norcantharidin.
Exp Ther Med. 18:3751–3758. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang SY, Chen CL, Hu YC, Chi Y, Huang YH,
Su CW, Jeng WJ, Liang YJ and Wu JC: High expression of
microRNA-196a is associated with progression of hepatocellular
carcinoma in younger patients. Cancers (Basel).
11(1549)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wu F, Zhang C, Cai J, Yang F, Liang T, Yan
X, Wang H, Wang W, Chen J and Jiang T: Upregulation of long
noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor
prognosis in glioma. Oncotarget. 8:53110–53123. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yang B, Wang C, Xie H, Wang Y, Huang J,
Rong Y, Zhang H, Kong H, Yang Y and Lu Y: MicroRNA-3163 targets
ADAM-17 and enhances the sensitivity of hepatocellular carcinoma
cells to molecular targeted agents. Cell Death Dis.
10(784)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhao Y, Chen J, Wei W, Qi X, Li C and Ren
J: The dual-inhibitory effect of miR-338-5p on the multidrug
resistance and cell growth of hepatocellular carcinoma. Signal
Transduct Target Ther. 3(3)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Forner A, Gilabert M, Bruix J and Raoul
JL: Treatment of intermediate-stage hepatocellular carcinoma. Nat
Rev Clin Oncol. 11:525–535. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pérez-Tomás R: Multidrug resistance:
Retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Song Y, Wang F, Huang Q, Cao Y, Zhao Y and
Yang C: MicroRNAs contribute to hepatocellular carcinoma. Mini Rev
Med Chem. 15:459–466. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fittipaldi S, Vasuri F, Bonora S,
Degiovanni A, Santandrea G, Cucchetti A, Gramantieri L, Bolondi L
and D'Errico A: miRNA signature of hepatocellular carcinoma
vascularization: How the controls can influence the signature. Dig
Dis Sci. 62:2397–2407. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Masood N, Basharat Z, Khan T and Yasmin A:
Entangling relation of micro RNA-let7, miRNA-200 and miRNA-125 with
various cancers. Pathol Oncol Res. 23:707–715. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hsu HH, Kuo WW, Shih HN, Cheng SF, Yang
CK, Chen MC, Tu CC, Viswanadha VP, Liao PH and Huang CY: FOXC1
regulation of miR-31-5p confers oxaliplatin resistance by targeting
LATS2 in colorectal cancer. Cancers (Basel).
11(1576)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ma C, Shi X, Guo W, Feng F and Wang G:
miR-205-5p downregulation decreases gemcitabine sensitivity of
breast cancer cells via ERp29 upregulation. Exp Ther Med.
18:3525–3533. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wu Y, Zhu X, Shen R, Huang J, Xu X and He
S: miR-182 contributes to cell adhesion-mediated drug resistance in
multiple myeloma via targeting PDCD4. Pathol Res Pract.
215(152603)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yang H, Fang F, Chang R and Yang L:
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting
transforming growth factor β receptor 1 and fibroblast growth
factor 9 in hepatocellular carcinoma. Hepatology. 58:205–217.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Han S, Wang L, Sun L, Wang Y, Yao B, Chen
T, Liu R and Liu Q: MicroRNA-1251-5p promotes tumor growth and
metastasis of hepatocellular carcinoma by targeting AKAP12. Biomed
Pharmacother. 122(109754)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang Y, Xia F, Zhang F, Cui Y, Wang Q,
Liu H and Wu Y: miR-135b-5p enhances doxorubicin-sensitivity of
breast cancer cells through targeting anterior gradient 2. J Exp
Clin Cancer Res. 38(26)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang Y, Ao X, Liu Y, Ding D, Jiao WJ, Yu
Z, Zhai WX, Dong SH, He YQ, Guo H, et al: MicroRNA-608 promotes
apoptosis in non-small cell lung cancer cells treated with
doxorubicin through the inhibition of TFAP4. Front Genet.
10(809)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gu N, Wang X, Di Z, Xiong J, Ma Y, Yan Y,
Qian Y, Zhang Q and Yu J: Silencing lncRNA FOXD2-AS1 inhibits
proliferation, migration, invasion and drug resistance of
drug-resistant glioma cells and promotes their apoptosis via
microRNA-98-5p/CPEB4 axis. Aging (Albany NY). 11:10266–10283.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Patil SL, Palat A, Pan Y, Rajapakshe K,
Mirchandani R, Bondesson M, Yustein JT, Coarfa C and Gunaratne PH:
MicroRNA-509-3p inhibits cellular migration, invasion, and
proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep.
9(19089)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Campaner E, Rustighi A, Zannini A,
Cristiani A, Piazza S, Ciani Y, Kalid O, Golan G, Baloglu E,
Shacham S, et al: A covalent PIN1 inhibitor selectively targets
cancer cells by a dual mechanism of action. Nat Commun.
8(15772)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zheng Y, Pu W, Li J, Shen X, Zhou Q, Fan
X, Yang SY, Yu Y, Chen Q, Wang C, et al: Discovery of a prenylated
flavonol derivative as a Pin1 inhibitor to suppress hepatocellular
carcinoma by modulating microRNA biogenesis. Chem Asian J.
14:130–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lu Z and Hunter T: Prolyl isomerase Pin1
in cancer. Cell Res. 24:1033–1049. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yeh ES and Means AR: PIN1, the cell cycle
and cancer. Nat Rev Cancer. 7:381–388. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Atkinson GP, Nozell SE, Harrison DK,
Stonecypher MS, Chen D and Benveniste EN: The prolyl isomerase Pin1
regulates the NF-kappaB signaling pathway and interleukin-8
expression in glioblastoma. Oncogene. 28:3735–3745. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pyo JS, Son BK and Oh IH: Cytoplasmic Pin1
expression is correlated with poor prognosis in colorectal cancer.
Pathol Res Pract. 214:1848–1853. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen M, Xia Y, Tan Y, Jiang G, Jin H and
Chen Y: Downregulation of microRNA-370 in esophageal squamous-cell
carcinoma is associated with cancer progression and promotes cancer
cell proliferation via upregulating PIN1. Gene. 661:68–77.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Girardini JE, Napoli M, Piazza S, Rustighi
A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson
A, et al: A Pin1/mutant p53 axis promotes aggressiveness in breast
cancer. Cancer Cell. 20:79–91. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yan X, Zhu Z, Xu S, Yang LN, Liao XH,
Zheng M, Yang D, Wang J, Chen D, Wang L, et al: MicroRNA-140-5p
inhibits hepatocellular carcinoma by directly targeting the unique
isomerase Pin1 to block multiple cancer-driving pathways. Sci Rep.
7(45915)2017.PubMed/NCBI View Article : Google Scholar
|
